
News|Articles|November 26, 2012
FDA panel votes against making oxybutynin transdermal patch OTC
An FDA advisory panel voted against making oxybutynin transdermal patch (Oxytrol, Merck and Watson Pharma) available over-the-counter (OTC) for overactive bladder (OAB) in women, Medpage Today reported.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Positive results for Casgevy but with one patient death from myeloablative busulfan conditioning | ASH 2025
2
Quadruplet treatments for multiple myeloma are rising but access varies | ASH 2025
3
AstraZeneca’s Imfinzi gains landmark FDA approval for early gastric and gastroesophageal cancers
4
IV iron treatment improves survival, increases hemoglobin levels in anemic patients with acute bacterial infection | ASH 2025
5






















































